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Introduction
Primary hepatic lymphoma (PHL) is confined to the liver with
no evidence of lymphomatous involvement in other lymphoid
structures. It is a very rare malignancy representing less than
1 % of all extra nodal lymphomas. The exact cause of PHL is
unknown, but it seems that there is a strong association
between hepatitis C virus (HCV) and PHL. The majority of
PHL patients are middle-aged men who usually present
nonspecific symptoms. Diagnosis of PHL requires a liver
biopsy compatible with lymphoma and the absence of
lympho-proliferative disease outside the liver. The rarity of
the disease leads to problems of diagnosis and management.
The optimal treatment is still unclear and the results are
uncertain.
We report a case of PHL developed in segment I of the
liver, and we present a review of the literature including
clinical, radiological, histological, and therapeutic features
of this disease.
This case report is approved by the patient herself.
Informed consent has been obtained from the patient for
publication of this case.
Case Report
A 65-year-old woman, without medical history, presented,
4 months earlier with abdominal pain associated with a
long-term fever and weight loss. The patient had no com-
plaints of vomiting, jaundice, or night sweats.
The physical examination on admission found an asthen-
ic patient with mild mucocutaneous pallor, a temperature of
38.5 °C and blood pressure of 120/70 mmHg. There was
also a slight abdominal distension but no signs of cirrhosis
or portal hypertension. The liver and spleen were normal in
size and lymph nodes were not enlarged.
Laboratory results including a blood cell count, an assess-
ment of cytolysis and cholestasis did not reveal any abnor-
malities. However, serologywas positive for hepatitis Cwith a
slightly elevated C-reactive protein levels at 60 mg/l. Tumor
markers (alpha-fetoprotein and carcinoembryonic antigen)
were normal. The chest X-ray was unremarkable.
Abdominal ultrasound showed a hypo-echoic tissue
mass developed in the caudate hepatic lobe with a well-
demarcated margin (Fig. 1). The abdominal computed to-
mography (CT) scan revealed that the tumor was hypo-
dense, well limited in the pre-contrast study and taking just
the contrast with peripheral vascular enhancement evoking a
hepatocellular carcinoma in the post-contrast study (Figs. 2
and 3). There was no evidence of biliary or pancreatic
disease, splenomegaly, or abdominal lymphadenopathy.
Radiography and CT scan of the chest did not reveal any
mediastinal lymphadenopathy. Endoscopic examinations of
the upper and lower gastrointestinal tracts were performed
but no abnormality was found.
Surgical exploration was indicated for hepatic carcinoma
evolving on an apparently healthy liver with a negative stag-
ing. During the intervention, it was found that there was an
encapsulated liver tumor at the expense of segment I. The
extra-tumor liver was healthy. Hepatic segmentectomy was
performed. Macroscopic study of the piece showed a hepatic
mass well-limited encapsulated with soft consistency measur-
ing 11.5×8×7 cm. The non-tumor part of the liver parenchy-
ma was normal. Microscopically, there was a heavy
infiltration composed mainly of large lymphoid cells.
Immunohistochemical staining demonstrated that the cells
were positive for CD20 and leukocyte common antigen.
Subsequently, a bone marrow biopsy was performed. It
showed normal cellularity with normal maturation of all cell
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lines. Thus, according to the absence of other foci of lympho-
ma, a diagnosis of diffuse large B cell primary hepatic lym-
phoma was established. The patient was referred to oncology
for chemotherapy. She received 8 cycles of CHOP protocol
(cyclophosphamide–doxorubicin–vincristine–prednisolone).
The postoperative course is simple. The patient is currently in
2-years follow-up with a good evaluation.
Discussion
Primary hepatic lymphoma (PHL) is defined as an
extranodal lymphoma of the liver without involvement of
any other organ (lymph node, bone marrow, spleen, etc.) [1,
2]. The primary non-Hodgkin lymphoma of the liver is a
rare condition that represents less than 1 % of all extra nodal
lymphomas [1]. It affects preferentially men (sex ratio of
three men to one woman) of mean age 50 years [3].
The etiology of this disease is still unknown. However, the
presence of chronic inflammation of the liver parenchyma
(hepatitis B or C), an EBV infection, or immunosuppression
(human immunodeficiency virus HIV) seems to play an im-
portant role in the pathogenesis of PHL [4–6]. Hepatitis C is
found in 40–60 % of patients with PHL [1], suggesting that
there is a strong association between HCV and non-Hodgkin
lymphoma of the liver. Our patient had hepatitis C, thus this
virus may play a role in the genesis of the disease.
Presentations vary from the incidental discovery in oth-
erwise asymptomatic patients to onset of fulminant hepatic
failure with rapid progression of encephalopathy to coma
and death. The symptoms are usually nonspecific. Patients
may report abdominal pain (right upper quadrant or epigas-
tric pain), nausea, fever, asthenia, weight loss, and anorexia.
Hepatomegaly is often present on clinical examination but
jaundice is rarely found.
Based on liver infiltration, PHL can be subdivided into
nodular or diffuse types. The predominant histology of PHL
is diffuse large B cell lymphoma [7, 8], as was the case for our
patient. Other histologic types described (less than 5 % of
cases) are immunoblastic, lymphoblastic, Burkett’s lympho-
mas, mucosa-associated lymphoid tissue lymphomas, ana-
plastic large-cell lymphoma, and rare cases of lymphoma T
cell [8].
Patients with PHL typically have abnormal liver function
tests, with elevation of lactate dehydrogenase (LDH) and
alkaline phosphatase. Hypercalcemia is observed in 40 % of
patients for unknown reasons, but the release of calcitriol by
malignant lymphoma cells is considered as a possible cause
[1, 2, 9–11]. In the case of hepatic tumor, elevated LDH,
with normal alpha-fetoprotein (AFP) and carcinoembryonic
antigen (CEA), remains a valuable biologic feature [5, 7]. In
our case, there are no biological abnormalities apart from a
positive serology for hepatitis C.
Ultrasound is a good screening test, showing classically
hypo-echoic lesions relative to normal liver [8, 12]. The
abdominal CT scan found hypo-attenuating masses,
unenhanced or poorly enhanced after contrast. The findings
with magnetic resonance imaging are variable, however, as
several authors have described lesions that appear hypo-
intense on T1-weighted and hyper-intense in T2-weighted
[2, 8, 12–14]. Liver biopsy remains the most valuable tool
for diagnosis of PHL. If a discrete mass is not visible on
imaging for percutaneous liver biopsy, the first transjugular
approach may be reasonable. Immunohistochemical typing
Fig. 2 Abdominal CT scan without contrast showing a hypo-dense
mass with regular contours, measuring 10×7 cm at the expense of the
caudate lobe of the liver
Fig. 3 Post-contrast abdominal CT scan shows the lesion with a well-
demarcated margin taking just the contrast with peripheral vascular
enhancement
Fig. 1 Abdominal ultrasound image showing a hypo-echoic mass
developed in segment I of the liver, with regular outlines
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is needed to differentiate lymphoma from other malignan-
cies. In our patient, liver biopsy was not performed because
we did not deem it essential to the near certainty of malig-
nancy made by morphological assessment and inherent risks
in this one particular swarming on the puncture tract. With
normal level of alpha-fetoprotein, our patient was mistaken
as having AFP-negative hepatic cancer before pathological
diagnosis. The histological diagnosis of lymphoma on liver
biopsy is not always possible; many patients are thus oper-
ated for erroneous diagnosis of carcinoma or other tumor.
Our observation illustrates this scenario.
Due to the rarity of this disease entity, the nonspecific
clinical presentation, and laboratory and radiological features,
PHL can be confused with focal nodular hyperplasia, primary
hepatic tumors, carcinoma with hepatic metastases, and
systemic lymphoma with secondary hepatic involvement
[2, 3, 6, 15].
The therapeutic modalities reported in the literature are
variable associating surgery, chemotherapy, radiotherapy, or
combination of the various processes [2, 3]. However, early
surgical treatment followed by chemotherapy seems to give
good performances and provide benefits in term of survival
[6, 16]. The indications for surgery are not well established,
although localized disease can be treated by liver resection
[16]. But it requires patients in good general condition in
absence of co-morbidities, with preserved liver function and
a tumor of small size [3]. Surgery is also used in order to
reduce tumor volume before or after chemotherapy [2, 3].
Poor prognostic features include advanced age, constitu-
tional symptoms, bulky disease, unfavorable histologic
subtype, elevated levels of LDH and β2-microglobulin, a
high proliferation rate, cirrhosis, and comorbid conditions
[17]. The appreciation of prognostic factors in our patient
through the assessment of his impaired general condition,
his advanced age, the absence of concomitant illness, and
isolated character of tumor enabled us to predict a moder-
ately good prognosis.
Conclusion
Primary hepatic lymphoma is a rare entity that should be
considered in any patient with liver mass or liver infiltration,
especially with normal levels of alpha-fetoprotein and CEA.
The rarity of the disease leads to problems of diagnosis and
management. The optimal treatment is still unclear and the
results are uncertain. Most patients are treated with multi-
agent chemotherapy, with some physicians employing a
multimodality approach. Surgery may be proposed in the
nodular forms, with a postoperative chemotherapy highly
recommended to reduce the rate of extra-hepatic recurrence.
The prognosis is variable depending on several factors.
Suppression from hepatic viral infections could be a curial
step in preventing carcinogenesis of PHL.
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